[go: up one dir, main page]

MX2013010016A - Compuestos de quinazolina sustituidos con alquino y metodos uso. - Google Patents

Compuestos de quinazolina sustituidos con alquino y metodos uso.

Info

Publication number
MX2013010016A
MX2013010016A MX2013010016A MX2013010016A MX2013010016A MX 2013010016 A MX2013010016 A MX 2013010016A MX 2013010016 A MX2013010016 A MX 2013010016A MX 2013010016 A MX2013010016 A MX 2013010016A MX 2013010016 A MX2013010016 A MX 2013010016A
Authority
MX
Mexico
Prior art keywords
methods
substituted quinazoline
alkyne substituted
quinazoline compound
compounds
Prior art date
Application number
MX2013010016A
Other languages
English (en)
Other versions
MX344302B (es
Inventor
Xiaoling Zheng
Wang Shen
Aimin Zhang
Jack Maung
Original Assignee
Newgen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newgen Therapeutics Inc filed Critical Newgen Therapeutics Inc
Publication of MX2013010016A publication Critical patent/MX2013010016A/es
Publication of MX344302B publication Critical patent/MX344302B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona compuestos de quinazolina sustituidos con alquino, tales como compuestos de la fórmula (I), los cuales son inhibidores de la quinasa ErbB irreversible. Los compuestos son útiles en el tratamiento de enfermedades y trastornos en donde la actividad de la quinasa ErbB está implicada como un trastorno hiperproliferativo (por ejemplo, cáncer).
MX2013010016A 2011-03-04 2012-03-02 Compuestos de quinazolina sustituidos con alquino y metodos uso. MX344302B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161449088P 2011-03-04 2011-03-04
PCT/US2012/027614 WO2012122058A2 (en) 2011-03-04 2012-03-02 Alkyne substituted quinazoline compound and methods of use

Publications (2)

Publication Number Publication Date
MX2013010016A true MX2013010016A (es) 2013-11-20
MX344302B MX344302B (es) 2016-12-13

Family

ID=46798728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010016A MX344302B (es) 2011-03-04 2012-03-02 Compuestos de quinazolina sustituidos con alquino y metodos uso.

Country Status (14)

Country Link
US (5) US9090588B2 (es)
EP (1) EP2680850B1 (es)
JP (1) JP6006242B2 (es)
KR (4) KR102061743B1 (es)
CN (1) CN103998040B (es)
AU (3) AU2012225693A1 (es)
BR (1) BR112013022552B1 (es)
CA (1) CA2828713C (es)
IL (1) IL228072A (es)
MX (1) MX344302B (es)
RU (1) RU2013144571A (es)
SG (3) SG10201913982WA (es)
TW (1) TWI617556B (es)
WO (1) WO2012122058A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122058A2 (en) * 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN102898386B (zh) * 2011-07-27 2015-07-29 上海医药集团股份有限公司 喹唑啉衍生物、其制备方法、中间体、组合物及其应用
WO2014177038A1 (en) 2013-04-28 2014-11-06 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
CN103254156B (zh) * 2013-05-10 2015-08-26 苏州明锐医药科技有限公司 阿法替尼中间体的制备方法
CN103254183B (zh) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 阿法替尼的制备方法
SG11201805286RA (en) * 2015-12-24 2018-07-30 Kyowa Hakko Kirin Co Ltd α,β-UNSATURATED AMIDE COMPOUND
DE102016224889B4 (de) * 2016-12-14 2019-11-07 Airbus Defence and Space GmbH Verfahren zur Vorbeugung einer Ablösung einer Fluidströmung, Strömungskörpersystem und Luftfahrzeug
US11083492B2 (en) * 2018-06-06 2021-08-10 Lifetech Scientific (Shenzhen) Co., Ltd Method for implanting an interventional medical device
US10973321B2 (en) 2018-09-04 2021-04-13 Steelcase Inc. Workspace system and components and method for the use thereof
MX2021003517A (es) 2018-09-25 2021-08-16 Black Diamond Therapeutics Inc Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
CA3150701A1 (en) * 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CN113527215B (zh) * 2020-04-17 2023-12-05 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
TWI820414B (zh) * 2020-04-17 2023-11-01 大陸商北京賽特明強醫藥科技有限公司 喹唑啉類化合物、製備方法及其應用
MX2023004998A (es) * 2020-11-02 2023-05-12 Black Diamond Therapeutics Inc Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.
WO2024179451A1 (zh) * 2023-03-02 2024-09-06 江苏康缘药业股份有限公司 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062881A (en) 1974-07-26 1977-12-13 Cincinnati Milacron Chemicals, Inc. Sulfide containing tin stabilizers
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
EP0326307B1 (en) 1988-01-23 1994-08-17 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
US5053227A (en) 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
JP3089901B2 (ja) 1993-07-20 2000-09-18 株式会社豊田自動織機製作所 クラッチレス圧縮機における動力伝達構造
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9405355D0 (en) 1994-03-18 1994-05-04 Lucas Ind Plc Vibrating element transducer
AU5108196A (en) 1995-03-20 1996-10-08 Dr. Karl Thomae Gmbh Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
ES2332984T3 (es) 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6020492A (en) 1995-05-12 2000-02-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
MX9709867A (es) 1995-06-07 1998-03-31 Pfizer Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
EP0832073B1 (en) 1995-06-07 2002-01-16 Sugen, Inc. Quinazolines and pharmaceutical compositions
ES2172670T3 (es) 1995-07-06 2002-10-01 Novartis Ag Pirrolpirimidinas y procedimientos para su preparacion.
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AU2522197A (en) 1996-04-16 1997-11-07 Ube Industries, Ltd. Hydrazine compounds, process for the preparation thereof, and insecticides for agricultural and horticultural use
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
TW533204B (en) 1998-07-30 2003-05-21 Wyeth Corp A process for preparing substituted quinazoline derivatives
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
ATE353891T1 (de) 2000-06-30 2007-03-15 Glaxo Group Ltd Ditosylatsalze von chinazolinverbindungen
SK287335B6 (sk) 2000-10-27 2010-07-07 Novartis Ag Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TWI309647B (es) 2001-02-21 2009-05-11 Mitsubishi Tanabe Pharma Corp
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
JP4353903B2 (ja) 2005-01-07 2009-10-28 東京エレクトロン株式会社 クラスタツールの処理システム
TW200716557A (en) 2005-05-25 2007-05-01 Wyeth Corp Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
SI1981863T1 (sl) 2006-01-26 2013-01-31 Boehringer Ingelheim International Gmbh Postopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
CN100345856C (zh) 2006-03-10 2007-10-31 武汉化工学院 一种制备葡萄糖醛酸内酯的酯化及结晶工艺方法
US8604044B2 (en) 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2008233930A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CN102686581B (zh) 2009-12-21 2015-08-26 张强 喹唑啉衍生物
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
WO2012122058A2 (en) 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途

Also Published As

Publication number Publication date
CN103998040B (zh) 2017-03-29
IL228072A (en) 2016-08-31
KR20210043016A (ko) 2021-04-20
TW201249835A (en) 2012-12-16
US20160031860A1 (en) 2016-02-04
KR20220031732A (ko) 2022-03-11
CA2828713A1 (en) 2012-09-13
AU2012225693A1 (en) 2013-09-19
AU2018267622A1 (en) 2018-12-13
TWI617556B (zh) 2018-03-11
MX344302B (es) 2016-12-13
AU2018267622B2 (en) 2020-05-14
WO2012122058A2 (en) 2012-09-13
US20210047303A1 (en) 2021-02-18
BR112013022552B1 (pt) 2021-11-23
US11524956B2 (en) 2022-12-13
EP2680850A4 (en) 2015-01-28
KR20140020955A (ko) 2014-02-19
US20180093975A1 (en) 2018-04-05
AU2017200984A1 (en) 2017-03-02
SG10201601711SA (en) 2016-04-28
US20190382382A1 (en) 2019-12-19
SG193291A1 (en) 2013-10-30
JP6006242B2 (ja) 2016-10-12
RU2013144571A (ru) 2015-04-10
US9090588B2 (en) 2015-07-28
US20140128417A1 (en) 2014-05-08
EP2680850B1 (en) 2018-05-23
CA2828713C (en) 2022-08-16
EP2680850A2 (en) 2014-01-08
JP2014518544A (ja) 2014-07-31
KR20200003933A (ko) 2020-01-10
SG10201913982WA (en) 2020-03-30
WO2012122058A3 (en) 2014-04-24
BR112013022552A2 (pt) 2016-12-06
CN103998040A (zh) 2014-08-20
IL228072A0 (en) 2013-09-30
KR102061743B1 (ko) 2020-01-03

Similar Documents

Publication Publication Date Title
MX2013010016A (es) Compuestos de quinazolina sustituidos con alquino y metodos uso.
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX362550B (es) Inhibidores ciclicos de glutaminasa.
IN2014MN02082A (es)
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
BR112015000399A2 (pt) derivados de pirazolil pirimidina
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
MX355088B (es) Inhibidores de tienopirimidina de proteina cinasa c atipica.
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
MY184561A (en) Substituted pyrimidine compounds and their use as syk inhibitors
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
MX353062B (es) Nuevas carboxamidas heterociclicas como moduladores de la activadad de cinasas.
MX2015000064A (es) Compuestos de acrilamida como ligandos receptores de histamina h3.
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.

Legal Events

Date Code Title Description
FG Grant or registration